OTC: HNSBF - Hansa Biopharma AB (publ)

Lønnsomhet i seks måneder: +2.39%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Hansa Biopharma AB (publ)

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

flere detaljer
The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.hansabiopharma.com
Цена ао 3
Prisendring over 3 måneder: -17.81% (3.65)
Prisendring over seks måneder: +2.39% (2.93)
Prisendring per år: -7.83% (3.255)
Prisendring over 3 år: -67.57% (9.25)
Prisendring over 5 år: -61.39% (7.77)
Prisendring siden begynnelsen av året: +6.01% (2.83)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 12.2 1
P/BV -3.55 0
P/E 0 0
EV/EBITDA -4.48 0
Total: 3.5

Effektivitet

Navn Betydning Karakter
ROA, % -14.6 0
ROE, % 70.78 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -1.75 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 250 10
Lønnsomhet Ebitda, % -81.29 0
Lønnsomhet EPS, % -83.89 0
Total: 2
Flere detaljer

Institusjoner Volum Dele, %
SPDR Portfolio Developed World ex-US ETF 115184 0.22
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF 30740 0.06
SPDR (R) Portfolio Europe ETF 611 0



Veileder Stillingstittel Betaling Fødselsår
Mr. Søren Tulstrup M.Sc President & CEO 16.12M 1965 (60 år)
Dr. Christian Kjellman Senior VP & COO N/A 1967 (58 år)
Dr. Hitto Kaufmann Ph.D. Chief Scientific Officer N/A 1971 (54 år)
Ms. Eva-Maria Joed Vice President of Finance & Administration N/A 1969 (56 år)
Mr. Klaus Sindahl VP & Head of Investor Relations N/A
Ms. Anne Säfström Lanner Senior VP & Chief Human Resources Officer N/A 1969 (56 år)
Mr. Emanuel Björne VP & Head of Business Development N/A 1973 (52 år)
Dr. Lena Winstedt Head of Science N/A 1969 (56 år)
Ms. Vincenza Nigro M.B.A. VP & Head of Medical Affairs N/A
Mr. C. Evan Ballantyne Chief Financial Officer N/A 1960 (65 år)

Adresse: Sweden, Lund, ScheelevAegen 22 - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.hansabiopharma.com